Mutant ubiquitin (UBB+1) associated with neurodegenerative disorders is hydrolyzed by ubiquitin C-terminal hydrolase L3 (UCH-L3)

  • Frank J. A. Dennissen
  • , Natalia Kholod
  • , Denise J. H. P. Hermes
  • , Nadja Kemmerling
  • , Harry W. M. Steinbusch
  • , Nico P. Dantuma
  • , Fred W. van Leeuwen*
  • *Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Mutant ubiquitin (UBB+1) accumulates in the hallmarks of tauopathies and polyglutamine diseases. We show that the deubiquitinating enzyme YUH1 of Saccharomyces cerevisiae and its mouse and human ortholog UCH-L3 are able to hydrolyze the C-terminal extension of UBB+1. This yields another dysfunctional ubiquitin molecule (UBG76Y) with biochemical properties similar to full length UBB+1. UBB+1 may be detected in post-mortem tissue due to impaired C-terminal truncation of UBB+1. Although the level of UCH-L3 protein in several neurodegenerative diseases is unchanged, we show that in vitro oxidation of recombinant UCH-L3 impairs its deubiquitinating activity. We postulate that impaired UCH-L3 function may contribute to the accumulation of full length UBB+1 in various pathologies. Crown Published by Elsevier B. V. on behalf of Federation of European Biochemical society. All rights reserved.
Original languageEnglish
Pages (from-to)2568-2574
Number of pages7
JournalFebs Letters
Volume585
Issue number16
DOIs
Publication statusPublished - 19 Aug 2011

Keywords

  • UBB+1
  • Ubiquitin C-terminal hydrolase L3
  • Yeast ubiquitin hydrolase 1
  • Alzheimer's disease

Fingerprint

Dive into the research topics of 'Mutant ubiquitin (UBB+1) associated with neurodegenerative disorders is hydrolyzed by ubiquitin C-terminal hydrolase L3 (UCH-L3)'. Together they form a unique fingerprint.

Cite this